Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Mar 14, 2022 10:00am
190 Views
Post# 34511343

RE:"Nitrogen Scavenging Properties"

RE:"Nitrogen Scavenging Properties"

This study result was 100% telegraphed and expected that they would tank 4050 despite the early success in fibrosis on Alstrom and IPF. So, someone is lying. Was it previous management of Pierre Laurin and Dr John Moran or was it Thomvest / current management who recapitalized PLi? With many trials completed previously with top scientists, they found strong fibrosis candidates. Now, with a technical team led by a consultant, it takes 15 months to deduce that there is no value to 4050 as a fibrosis drug? 

if they knew there was no value to 4050 in fibrosis, why would they give Pierre Laurin's company $400k and a royalty stream for the IP last month?  Why would Thomvest get rid of their top scientists like Lynn Gagnon who led 4050 development when small molecule division was where their focus would be. As usual, something is rotten in the state of PLI. 

 

37minus4 wrote: Well that is some thin gruel, boy.

Maybe they can add some of their "scavenged nitrogen" to the poutine in the poutine shack.

Tasty.

;-/

33

 

<< Previous
Bullboard Posts
Next >>